Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early protection against meningococcal B disease in infants
ISRCTN52318758Phase 4Completed
- Sponsor
- St George's, University of London
- Start
- Jul 2021
01
Overview
Phase 4, randomised, open-label trial of meningococcal group B vaccine in meningococcal disease (2 arms), sponsored by St George's, University of London. Primary endpoints: Antibody geometric mean titers against 4CMenB antigens after second dose and Proportion with protective antibody titers against 4CMenB antigens after second dose. Started Jul 2021; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on ISRCTN52318758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52318758.